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Whilst the role of the Disrupted-in-Schizophrenia 1 (DISC1) gene in the aetiology of major mental 
illnesses is debated, the characterisation of its function lends it credibility as a candidate. A key 
aspect of this functional characterisation is the determination of the role of common non-
synonymous polymorphisms on normal variation within these functions. The common allele (A) 
of the DISC1 SNP rs821616 encodes a serine at the Ser704Cys polymorphism, and has been 
shown to increase the phosphorylation of extracellular signal-regulated protein Kinases 1 and 2 
(ERK1/2) which stimulate the phosphorylation of tyrosine hydroxylase, the rate-limiting enzyme 
for dopamine biosynthesis. We therefore set out to test the hypothesis that human serine (A) 
homozygotes would show elevated dopamine synthesis capacity compared to cysteine 
homozygotes and heterozygotes (TT and AT) for rs821616. [18F]-DOPA PET was used to index 
striatal dopamine synthesis capacity as the influx rate constant Kicer in healthy volunteers DISC1 
rs821616 serine homozygotes (N=46) and healthy volunteers DISC1 rs821616 cysteine 
homozygotes and heterozygotes (N=56), matched for age, gender, ethnicity and using three 
scanners. We found DISC1 rs821616 serine homozygotes exhibited a significantly higher striatal 
Kicer compared to cysteine homozygotes and heterozygotes (p=0.012) explaining 6.4% of the 
variance (partial eta squared=0.064). Our finding is consistent with its previous association with 
heightened activation of ERK1/2, which stimulates tyrosine hydroxylase activity for dopamine 
synthesis. This could be a potential mechanism mediating risk for psychosis, lending further 
credibility to the fact that DISC1 is of functional interest in the aetiology of major mental illness.
Introduction
The dopamine hypothesis has been a leading theory underlying the neurobiology of 
schizophrenia for the last four decades (1, 2). The hypothesis was initially based on evidence 
showing that antipsychotic medications block dopamine receptors (3–5) and that drugs 
increasing dopamine levels elicit psychotic symptoms in healthy people (6–8) and people 
with schizophrenia (9, 10). Using [18F] fluoro-3,4-dihydroxyphenyl-L-alanine (F-DOPA) 
Positron Emission Tomography (PET), increased presynaptic dopamine synthesis capacity 
has been found in schizophrenia (11), people with prodromal psychotic symptoms (12, 13) 
and those with clinical progression to psychosis (14). Whilst a substantial body of evidence 
supports the role of increased presynaptic dopamine synthesis capacity in the pathoaetiology 
of psychosis, little is known about how genetic factors affect the implicated dopamine 
system(s) (15).
The Disrupted-in-Schizophrenia 1 (DISC1) gene was originally discovered at the breakpoint 
of a balanced t(1;11) (q42;q14.3) translocation in a Scottish family with a high-prevalence of 
psychiatric disorders including schizophrenia (16–18). Further evidence for a link between 
DISC1 and psychotic and affective disorders emerged from the follow-up of families 
displaying rare DISC1 mutations (19, 20) and large family-based studies in the population 
isolate of Finland (21‒23) although a large meta-analysis of families did not observe linkage 
at this region (24). Furthermore, evidence from individual population-based cohorts has been 
inconsistent (25, 26) leading to ongoing debate on its involvement in schizophrenia (27, 28). 
Whilst this controversy remains unresolved, there is value in seeking convergent evidence 
via studies elucidating the functional impact of the gene and its variations (29–32). DISC1 is 
a scaffold protein involved in a wide range of neuronal functions including neuro-signalling 
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(30, 33). Preclinical studies show that DISC1 variant models exhibit increased 
amphetamine-induced dopamine release in the ventral striatum (see (34–37) reviewed in 
(38), indicating that DISC1 variations might affect presynaptic dopamine synthesis capacity.
One of the most studied DISC1 single nucleotide polymorphisms (SNPs) is rs821616 which 
is a non-synonymous mutation leading to the translation of a serine (A allele) or a cysteine 
(T allele) at codon 704 in exon 11 (39). Importantly, this polymorphism represents therefore 
not only a variation at the genetic sequence level but also at the protein sequence level of 
DISC1. At a molecular level, Hashimoto et al. (2006) found that overexpression of the serine 
variant of codon 704 by viral transduction resulted in a significant increase in 
phosphorylated ERK1/2, the more biologically active form (40). ERK1/2 in turn regulates 
the state of phosphorylation of tyrosine hydroxylase, the rate-limiting enzyme for dopamine 
biosynthesis, to increase its activity and subsequent dopamine synthesis by up to two-fold 
(41–44). Dopamine is synthesized by converting first tyrosine into dihydroxyphenyl-L-
alanine (L-DOPA) by tyrosine hydroxylase, and second dihydroxyphenyl-L-alanine (L-
DOPA) into dopamine by aromatic acid decarboxylase (45). [18F]-DOPA PET signal reflects 
aromatic acid decarboxylase function and dopamine storage capacity (45), but not directly 
tyrosine hydroxylase function. However, it should be noted that 1) tyrosine hydroxylase is 
the rate limiting step for dopamine synthesis capacity (43) and 2) the topological distribution 
of the [18F]-DOPA signal correlates highly with tyrosine hydroxylase immunostaining in 
unilaterally 6-hydroxydopamine (6-OHDA)-lesioned rats, thus indicating that the [18F]-
DOPA signal is strongly influenced by endogenous dopamine formed by tyrosine 
hydroxylase (46).
In summary, preclinical findings suggest that the Ser704Cys variation affects dopamine 
synthesis by regulating ERK1/2 and its control over tyrosine hydroxylase activity. However, 
it remains unknown whether the Ser704Cys variation is associated with altered dopamine 
synthesis in humans. The aim of this study was therefore to test the hypothesis that serine 
homozygotes would exhibit increased striatal dopamine synthesis capacity relative to 
cysteine homozygotes and heterozygotes.
Results
Demographics, scan parameters including the injected dose and substance use characteristics 
are shown in table 1. A total of 46 serine homozygotes and 56 cysteine homozygotes and 
heterozygotes (which encompass 45 heterozygotes and 11 cysteine homozygotes) were 
included in the study. The genotype frequencies (shown in table 1) did not significantly 
deviate from Hardy–Weinberg equilibrium (χ2 =1.422 with p=0.233), with a Minor Allele 
Frequency (T allele) of 0.335. Age (year) and Kicer (1/min) in the striatum were normally 
distributed across the two groups whereas injected dose (MBq) was not. There was no 
significant difference in age between groups t(100)=1.588, p=0.115 (independent t test) and 
no significant difference in injected dose p=0.408 (Mann Whitney test). Levene’s test 
indicated no difference between the variances in the two groups, F=0.398, p=0.529. The 
univariate ANCOVA showed that the main effect of the DISC1 SNP rs821616 on the 
dopamine synthesis capacity in the striatum was significant, F (1,96) = 6.555, p=0.012, 
partial eta squared =0.064. The effects of the covariates were: for scanner, F(1,96)=16.573, 
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p<0.01, age, F(1,96)=1.056, p=0.307, gender, F(1,96)=0.114, p=0.736 and ethnicity, 
F(1,96)=0.061, p=0.805.
Discussion
In line with our hypothesis, we found that participants serine homozygotes (AA genotype) 
for the Ser704Cys functional DISC1 polymorphism exhibited a significantly greater Kicer 
value in the striatum, indicating greater dopamine synthesis capacity compared to cysteine 
homozygotes and heterozygotes (AT or TT genotype). This result is in accordance with 
preclinical evidence showing that the serine 704 DISC1 variant increases the activity of 
ERK1/2, which in turn enhances the phosphorylation of tyrosine hydroxylase, the rate 
limiting step in dopamine synthesis (41, 47).
Limitations
The main limitation of this study was that we used data from three different PET scanners, 
which could add error variance. However, scanner was included as a covariate to adjust for 
this. Furthermore, the effect of the Ser704Cys polymorphism remained significant when we 
only included subjects from PET scanner 2 (F(1,28) = 5.273, p=0.029 (N=16 cysteine 
homozygotes and heterozygotes, N=17 serine homozygotes)), but not PET scanner 1 only 
(F(1,30) = 0.766, p=0.388, (N=19 cysteine homozygotes and heterozygotes, N=16 serine 
homozygotes)) and PET scanner 3 only (F(1,29) = 0.426, p=0.519, (N=21 cysteine 
homozygotes and heterozygotes, N=13 serine homozygotes)). It is important to recognise 
that we measured the final step in the synthesis of dopamine, the conversion of L-DOPA into 
dopamine via aromatic acid decarboxylase (AADC). However, the parameter measured 
could be affected by other variables including the uptake of L-DOPA into the brain, although 
this should be controlled for by the reference region and there is no a priori reason to 
consider that this should be affected by the DISC1 protein. Importantly, this polymorphism 
was chosen based on a specific prior hypothesis. Although there was evidence to reject the 
null hypothesis, the p-value would not survive genome-wide correction and therefore the 
result requires replication.
Implications for mental disorders
The Ser704Cys polymorphism has been associated with schizophrenia with an odds ratio in 
the range of 1.3 – 4.18 in various populations including European (48), mixed European/
African-American (49), and Chinese Han (50–52). Inconsistencies have been found, with 
some studies indicating increased risk associated with the serine (A) allele (48, 51), whilst 
others the cysteine (T) (allele) (50, 52) and no association found (25) mainly in the Japanese 
population (53–55). A recent meta-analysis has also reported association of the serine allele 
with schizophrenia in Chinese (OR=1.338) and Japanese populations (OR=1.524), as well as 
in the overall mixed race sample (56). The inconsistencies in these results might be due to 
different ethnic populations. It should be noted that ever expanding studies of European 
ancestry population level genetic variants in schizophrenia continually demonstrate no 
significant associations at the entire DISC1 locus (57, 58), although there is evidence 
implicating the DISC1 interactor phosphodiesterase 4B (PDE4B) as a genome-wide 
significant single gene locus in a recent large schizophrenia genome-wide association study 
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(GWAS) (58). Whilst GWAS have made crucial advances in the understanding of the genetic 
of schizophrenia, the biological mechanisms directly underlying the disorder remain yet 
poorly elucidated (59–61). In this context, the DISC1 protein has been suggested as a 
biological candidate of interest for investigating molecular mechanisms of mental illnesses 
at the protein levels (33, 62). Beyond studies of dichotomous diagnoses, the serine allele has 
also been associated with increased risk for poor concentration among Korean patients with 
schizophrenia (63), increased severity of positive symptoms and hallucinations in European 
patients with First-Episode Psychosis (64) and increased lifetime severity of delusions in 
European patients with schizophrenia (65). A potential mechanism for the increased risk 
could be by dysregulating the control of dopamine to lead to increased dopamine synthesis. 
Findings in prodromal populations show that increased dopamine synthesis is associated 
with increased risk for psychosis (12, 13). The difference in dopamine synthesis capacity we 
observe here between serine homozygotes and carriers of the alternative allele is much 
smaller than the differences seen in at risk subjects (14, 66). It is therefore likely that the 
Ser704Cys variant interacts with other genetic changes to mediate risk, potentially by 
affecting dopamine synthesis.
The fact that the common serine allele has been described as the risk allele is compatible 
with schizophrenia GWAS, in which approximately 50% of the implicated index SNPs are 
the more common alleles (67). At the population level, the genetic susceptibility to 
schizophrenia is caused by a few rare variants of high penetrance (mainly copy number 
variants and translocations) and many common variants of small penetrance (SNPs and 
variable number of tandem repeats) (68). As each SNP very minimally impacts 
schizophrenia risk and is compatible with modern models of natural selection (67), it is 
expected that other genetic factors are needed, in the same individual, to increase the 
liability to a point of schizophrenia onset. For example, the Ser704Cys site affects 
interaction with nuclear distribution element-like 1 (NDEL1) and its homolog Nuclear 
Distribution Element 1 (NDE1, also known as NudE) (69, 70), and there is evidence for an 
interaction between NDEL1 rs1391768 and the Ser704 allele and the NDE1 rs3784859 and 
the Cys704 allele on the risk for schizophrenia in European participants (71). Ser704Cys is 
also the binding site for proteins such as kendrin (also known as pericentrin PCNT) and 
Pericentriolar material 1 (PCM1) (72), which have been both described as risk factor genes 
for schizophrenia (73). Furthermore, environmental factors such as exposure to psychosocial 
stress may also interact with the Ser704Cys polymorphism to affect dopamine function and 
mediate risk for schizophrenia (15). Interestingly, using a transgenic expression of truncated 
human Disc1 protein with dominant-negative effect, Niwa et al. have shown that an 
interaction between DISC1 and stress exposure, as a 3 week social isolation paradigm, 
increased dopamine release after amphetamine challenge (34) and induced alterations in 
DNA methylation of the tyrosine hydroxylase gene (74).
Evidence also suggests that the Ser704Cys polymorphism is a risk factor for affective 
disorders. The cysteine allele has been associated with major depression in Japanese 
population (47), and shown to form a protective haplotype for bipolar spectrum disorder 
with two others DISC1 SNPs (rs1411771 and rs980989) in Finnish population (75), whereas 
a higher serine allele rate has been found in South Indian population with bipolar disorder 
(76). Interestingly, increased dopamine synthesis capacity is seen in both mania (77) and 
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bipolar psychosis (78), whilst major depression with affective flattening is characterized by a 
decreased synthesis capacity (79, 80).
The Ser704Cys SNP has also been shown to have a functional impact at the brain level (39). 
Compared to healthy cysteine homozygotes and heterozygotes, serine homozygotes display 
increased (for the same level of performance, thus putatively inefficient) prefrontal cortex 
activation in the left middle and left superior frontal gyri and in the homologous right 
superior frontal gyrus, the left inferior frontal and cingulate cortex, the thalamus and the 
caudate nucleus in a verbal fluency task (81), as well as an effect on thalamic-prefrontal 
connectivity (82). Ser704Cys SNP has also been shown to affect activation during 
declarative memory task with inconsistent findings. Callicott et al (48) found decreased 
activation bilaterally in the hippocampal formation during a declarative memory task and 
increased activation bilaterally in the hippocampal formation in an N-back task in Ser704 
homozygotes controls compared to cysteine homozygotes and heterozygotes, whereas Di 
Giorgio et al (83) found increased hippocampal formation/dorsolateral prefrontal cortex 
coupling during memory encoding in a declarative memory task in serine homozygotes 
compared to healthy cysteine homozygotes and heterozygotes.
In summary, our results provide unprecedented preliminary evidence that DISC1 Ser704Cys 
has an impact on the dopamine synthesis capacity, in a large sample of 102 healthy 
volunteers. Further studies should aim at 1) replicating this result in different cohorts; 2) 
investigating potential epistatic interactions with DISC1 and other risk genes. Genetic 
studies based on molecular evidence could help identify the molecular mechanism that 
underlies the pathoaetiology of dopamine-related disorders such as psychotic disorders, and 
help identify novel potential treatment targets (15).
Conclusion
We found that the serine allele of DISC1 Ser704Cys (rs821616) was associated with 
significantly higher striatal dopamine synthesis capacity, consistently with its previous 
association with heightened activation of ERK1/2 which stimulates tyrosine hydroxylase 
activity for dopamine synthesis. This implicates the DISC1 polymorphism in altering a 
psychosis relevant mechanism in the brain i.e. the facilitation of greater dopamine synthesis 
capacity. Although, this effect of rs821616 may be of too small effect to be identified in 
population-based studies of end state diagnoses at their current large size, it continues to 
implicate the functional role of DISC1. Firstly by highlighting the role of this polymorphism 
at this gene in creating variation within the normal functioning of the brain, but also by 
indicating this function as a potential mechanism through which other rare or familial 
mutations for major mental illnesses could disrupt functioning and increase risk to these 
devastating disorders.
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Material and Methods
Overview
All participants gave informed written consent to take part after full description of the study. 
All studies were approved by the institutional review board and the local research ethics 
committee.
Participants
Participants were recruited via advertisement in local media based in London. One hundred 
and twenty-three participants underwent a [18F]-DOPA PET scan. For all participants the 
inclusion criteria were 1) age above 18 years; 2) capacity to give written informed consent. 
The exclusion criteria were 1) any current medical conditions or history of medical 
condition (past minor self-limiting conditions were permitted); 2) history of a psychiatric 
disorder as determined by the Structured Clinical Interview for DSM-IV Axis 1 Disorders, 
Clinician Version (SCID-CV) (84); 3) history of substance abuse/dependence as determined 
by the Structured Clinical Interview for DSM-IV Axis 1 Disorders, Clinician Version 
(SCID-CV) (84); 4) history of head injury with a loss of consciousness; 5) a family history 
of any psychotic disorder in first- or second-degree relatives; 6) contraindications to positron 
emission tomography (PET) scanning (significant prior exposure to radiation, pregnancy or 
breast feeding). All participants provided urine samples prior to the scan to screen for drug 
use and pregnancy test in women. Six participants were excluded due to positive urine THC 
screening, 12 participants were excluded to contamination of samples and 3 participants 
were excluded due to current psychotropic medication use. This resulted in the final 
inclusion of 102 participants (46 females/56 males, age: 30.2±9.3 years (mean±Standard 
Deviation). Both scanning and imaging analysis were done blind to the genotype status.
[18F]-FDOPA PET
PET data were acquired using three different PET scanners. PET scanner 1 was an ECAT 
HR+ 962 PET scanner (CTI/Siemens, Knoxville, Tennessee). The dynamic images were 
acquired in 3D mode with an axial field of view of 15.5 cm and reconstructed using 
filterback projection. PET scanners 2 and 3 were two Siemens Biograph HiRez XVI PET-
CT scanner (Siemens Healthcare, Erlangen, Germany) at Imanova, Centre for Imaging 
Sciences. PET scanner 1 and PET scanner 2-3 were identical with the only exception of the 
axial field of view: 16.2 cm vs 21.6 cm respectively. The dynamic images were also 
reconstructed using a 3D filtered back-projection algorithm (discrete inverse Fourier 
transform, DIFT) with a 128 matrix, a zoom of 2.6 and a 5mm isotropic Gaussian 
smoothing. Participants were scanned at various times of the day. Some of the imaging data 
has been included in prior reports but not for genetic analysis (85–88). For attenuation and 
model-based scatter correction, a 10 min transmission scan was performed using a 150-MBq 
cesium-137 rotating point source for the ECAT HR+ 962 PET scanner and a computed 
tomography scan (effective dose=0.36 mSv) for the Siemens Biograph HiRez XVI PET-CT 
scanners were acquired prior to each PET scan. Experimental protocol was consistent for all 
the participants (85). Participants were asked to fast and abstain from smoking from 
midnight on the day of the scan as tobacco use has been associated with increased striatal 
dopamine synthesis capacity (89) although this has not been replicated (85). Oral doses of 
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carbidopa (150mg) and entacapone (400mg) were administrated 1 hour before scanning. 
While the first reduces the peripheral metabolism of the tracer (90), the latter minimizes the 
formation of radiolabeled [18F]-FDOPA metabolites, which can cross the blood-brain barrier 
(91). Head movement was monitored and minimized with a light head strap. If participants 
moved extensively during the acquisition or got out of the scanner a second attenuation 
correction image was acquired at the end of the acquisition. PET data were acquired 
dynamically during 95 minutes after bolus injection of the radioactive tracer [18F]-DOPA 
through a cannula inserted into a vein. Dynamic data were binned into 26 frames (PET 
scanner 1) and 32 frames (PET scanner 2 and 3).
Image Analysis
Head movement was corrected using a frame-by-frame realignment and denoising algorithm 
(92) with a level 2 order 64 Battle-Lemarie wavelet filter applied on the non- attenuation-
corrected dynamic images. These images were used because they include a significant scalp 
signal compared to attenuation-corrected images (93). Frames were realigned to a reference 
frame corresponding to the frame with the highest number of counts, i.e. obtained 7 minutes 
(for the ECAT HR+ 962 PET scanner-CTI/Siemens, Knoxville, Tennessee) and 17 minutes 
(for the Siemens Biograph HiRez XVI PET-CT scanners-Siemens Healthcare, Erlangen, 
Germany) after the radiotracer injection using a mutual information algorithm (94). The 
transformation parameters were then applied to the corresponding attenuation-corrected 
dynamic images. These realigned frames were summated, creating a movement-corrected 
dynamic image from which to extract the Time Activity Curves (TAC) for graphical analysis 
quantification. Standardized regions in Montreal Neurologic Institute (MNI) space were 
defined in the striatum delineated as previously described to create a Region of Interest 
(ROI) map (95) and in the cerebellum using the probabilistic Martinez atlas (95, 96). The 
cerebellum was used as a reference region as it is largely devoid of dopaminergic neurons or 
projections (45). A nonlinear transformation procedure on SPM8 (http://
www.fil.ion.ucl.ac.uk/spm) was used to normalize the ROI map together with the [18F]-
DOPA template to each individual PET summation image, in order to place the ROI 
automatically on individual [18F]-DOPA PET dynamic images. Influx constant Kicer value, 
(min-1) for the striatum was calculated relative to uptake in the reference region using a 
graphical approach (97), a method which has been shown to have good reliability (95).
Genetic analysis
DNA was extracted from blood or cheek swabs using standard methods (98). Genotyping of 
the rs821616 A>T SNP, was performed by KBioscience (Herts, UK, http://
www.kbioscience.co.uk) using a competitive allele specific Polymerase Chain Reaction 
system (CASP). Quality control procedures included negative control (water) wells and 
duplicate wells.
Statistical analysis
The normality of the distribution for all variables was examined using the Shapiro Wilk test, 
inspection of Q-Q plots and skewness and kurtosis values within range of ± 2. Homogeneity 
of variance was assessed with Levene’s Test for Equality of Variances. An alpha threshold 
was set at 0.05 (two-tailed) for significance for all statistical comparisons. Statistical 
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Package for the Social Sciences (SPSS) version 24 was used for all statistical analysis (IBM, 
Armonk, N.Y.). All data are shown as mean±SD. An univariate analysis of covariance 
(ANCOVA) was performed on 102 healthy controls, with the DISC1 SNP Ser704Cys 
variation (serine homozygotes versus cysteine homozygotes and heterozygotes) as the 
independent variable, Kicer in the striatum as the dependent variable and age, gender, 
ethnicity (table 1) and the three PET scanners separately as covariates as these variables 
have been previously found to influence dopamine synthesis capacity (99, 100). Effect sizes 
are reported as partial eta squared. Independent t test and Mann-Whitney test were used to 
compare age and injected dose.
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Figure 1. 
Mean (SEM) striatal dopamine synthesis capacity (Kicer value, min-1) in DISC1 rs821616 
cysteine homozygotes and heterozygotes (TT and TA, N=56) and DISC1 rs821616 serine 
homozygotes (AA, N=46). Dopamine synthesis capacity was significantly increased in 
serine homozygotes compared with cysteine homozygotes and heterozygotes (F 
(1,96)=6.555, p=0.012).
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Table
Table 1 DISC1 SNP rs821616
Total cysteine homozygotes and heterozygotes serine homozygotes P value
Total genotype counts 102 45 (AT) and 11 (TT) 46 (AA)
Females 46 21 25
PET scanner 1 35 19 16 0.549 iii
PET scanner 2 33 16 17
PET scanner 3 34 21 13
Age 30.2 (9.3) 31.5 (9.9) 28.6 (8.4) 0.115i
Tobacco smoking status (nonsmoker) 75 43 32 0.411ii
Tobacco smoking status (smoker) 27 13 14
Radioactivity injected (MBq) 157.7 (16.2) 156.6 (16.2) 159.2 (16.4) 0.529ii
White European 70 35 35 0.503iii
Black British/other 22 15 7
Asian British/other 5 3 2
Mixed ethnicity 5 3 2
All data ± SD.
i
Independent t test
ii
Mann-Whitney U test
iii
Pearson Chi-Square
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